Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
This article was originally published in PharmAsia News
Executive Summary
In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10
You may also be interested in...
Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)
Major Japanese pharmas face many of the same problems as major Western pharmas, including patent cliffs and growth slowdown in traditional markets. Japanese pharmas, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News.
Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)
Major Japanese pharmas face many of the same problems as major Western pharmas, including patent cliffs and growth slowdown in traditional markets. Japanese pharmas, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News.
Eisai Threatens To End Pfizer Alliance On Aricept Following Wyeth Acquisition
TOKYO - Eisai announced that it "has the right" to terminate a product development and business alliance agreement for its Alzheimer's treatment Aricept (donepezil) if Pfizer acquires Wyeth